Results 41 to 50 of about 149 (136)
Using a preclinical pancreatic cancer model, we identified that tumor progression restructures splenic immunity via myeloid cell expansion. MDCa@RBC‐Alipo nanobiologics were engineered to epigenetically and metabolically reprogram splenic myeloid cells, alleviating post‐ablation immunosuppression.
Shengbo Wu+12 more
wiley +1 more source
The Fe3O4/Gd@BSA‐pPB nanoprobe leverages biomimetic mineralization and targets hepatic stellate cells (HSCs) through PDGFRβ, offering superior enrichment in fibrotic regions. This targeted delivery overcomes biological barriers, enhancing both the accuracy and sensitivity of MRI imaging at early disease stages.
Zehua Li+11 more
wiley +1 more source
GLS1 is a novel contributor to arterial calcification. GLS1‐catalyzed glutamate exerts the promoting effects on osteogenic reprogramming in arteries. NMDAR, a glutamate receptor, is also activated and overexpressed during arterial calcification.
Ziting Zhou+18 more
wiley +1 more source
piR‐RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX‐1 Cytoplasm Localization
PIWI‐interacting RNAs (piRNAs), a novel category of small non‐coding RNAs, have been implicated in the development of various diseases. This study explores the tumor‐suppressive mechanism of a downregulated piRNA (designated piR‐RCC) in renal cell carcinoma (RCC), and provides a delivery strategy targeting RCC tumor by constructing a cell membrane ...
Ruyue Wang+16 more
wiley +1 more source
This study investigates the role of macrophage pyruvate carboxylase (PC) in atherosclerosis (AS) demonstrating that PC upregulation in macrophages promotes metabolism reprogramming to enhance inflammatory responses via the HIF‐1 signaling pathway.
Ling‐Na Zhao+17 more
wiley +1 more source
PRMT1 drives carboplatin resistance and tumor progression in head and neck squamous cell carcinoma (HNSCC) through a novel, methyltransferase‐independent mechanism. It recruits the SWI/SNF complex to activate IGF2BP2, promoting tumor growth and carboplatin resistance. PBX2 upregulates PRMT1, reinforcing this pathway. This study uncovers a non‐catalytic
Shixian Liu+22 more
wiley +1 more source
This study provides new perspectives into the interactions between mechanical forces and cellular dynamics within the tumor microenvironment, particularly elucidating how minority Paclitaxel‐resistant cancer cells (MRCs) promote tumor progression and treatment resistance through mechanical forces and also providing effective treatment strategies for ...
Xueyan Feng+12 more
wiley +1 more source
Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury
Dipyridamole acts as a clinically used compound to suppress ferroptosis. Dipyridamole down‐regulates the expression of RNF126, which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. The deficiency of SLC7A11 largely abolishes the protective role of dipyridamole both in vitro and in vivo.
Xiao Zhuang+22 more
wiley +1 more source
Ovarian cancer‐derived extracellular vesicles (EVs) transfer INAVA mRNA to normal ovarian fibroblasts (NOFs). Translated INAVA protein inhibits HMGA2 phosphorylation‐dependent ubiquitylation and proteasomal degradation, promoting NOF activation.
Lingkai Gu+12 more
wiley +1 more source
3D‐cultured renal cancer cells exhibit stem‐like phenotypes and are more efficient in generating bone metastases. Vitamin C treatment can suppress the development of bone metastasis. Single‐cell transcriptomic analysis reveals that vitamin C inhibits metastasis by inducing tumor cell cycle arrest, suppressing osteoclast differentiation, and reducing ...
Jianye Zhang+17 more
wiley +1 more source